T
he HIV Organ Policy Equity (HOPE) Act now permits transplantation using organs from HIV-positive donors to HIV-positive recipients in the United States. This historic law brings ethical opportunities and challenges.
Acquiring organs from those known or suspected to be HIV-positive has been banned since 1988. The ban was instituted at a point in the AIDS epidemic when there was no effective treatment, diagnostics were unreliable, and there was a clear risk for transmission with blood products. Given the broad ethical mandate to avoid harm, this policy made sense at the time.
Since then, the landscape has changed dramatically. Effective antiretroviral therapy (ART) has transformed HIV infection from a death sentence to a chronic disease in many parts of the world. Although morbidity and mortality from infections have sharply decreased, the burden of other complications, including end-stage renal disease and end-stage liver disease, has grown proportionally as people with HIV live longer (1, 2) . Large studies demonstrate a clear benefit of organ transplantation with HIV-negative donors for HIV-positive patients with end-stage organ disease. However, access to transplantation remains limited for HIV-positive individuals because not all centers have adopted this practice and HIV-positive individuals face disproportionately higher mortality while awaiting this life-saving therapy. Thus, both the need for organ transplantation among HIV-positive patients and an ethical obligation to provide such treatments have increased.
Unfortunately, this expanded eligibility for transplantation exacerbates an already existing shortage of available organs in the United States. Fairly resolving questions of allocation during scarcity is a familiar ethical problem in organ transplantation for which complex algorithms have been implemented (3) . Nonetheless, many patients die because of the lack of available organs. Accordingly, a morally prudent course is to seek safe and effective means to attenuate organ scarcity. One such approach involves the use of infected donors for recipients infected with the same pathogen.
Building on the success of using organs infected with hepatitis C virus for kidney and liver transplants (4 -6), in 2010 a small case series from South Africa demonstrated that kidney transplantation using HIVpositive deceased donors for HIV-positive recipients was feasible and that early outcomes were reasonable (7). In the United States, a study based on national registries estimated that there could be 500 to 600 HIVpositive deceased donors annually (8) . These data suggested that the federal restriction on the use of HIVpositive organs was problematic in determining whether such organs could be used safely to provide needed transplants for HIV-positive patients and to indirectly mitigate organ scarcity in general.
Consequently, the HOPE Act was proposed in 2011. This proposed policy change was officially endorsed by the American Medical Association and supported by dozens of transplant organizations, other medical organizations, and HIV advocacy groups. Despite broad support from the public and scientific community, obtaining congressional and White House attention took time (9) . Ultimately, the HOPE Act was unanimously passed by the U.S. House of Representatives and Senate and signed into law by President Obama on 21 November 2013, with a phased implementation period of 2 years (9, 10).
The HOPE Act had a 3-part mandate. First, the Department of Health and Human Services (DHHS) was required to revise the long-standing federal ban on HIV-positive organ donors, which was accomplished on 8 June 2015 (10 (12) .
Our institution opened the first clinical trial under these criteria and received approval from OPTN on 8 January 2016 (NCT02602262). The objective of this trial is to evaluate the safety of HIV-positive-to-HIV-positive kidney and liver transplantation and to assess the survival benefit of accepting an HIV-positive organ compared with waiting for an HIV-negative donor.
In this article, we review some inherent ethical issues and concerns that accompany such transplantations. Some of these concerns were raised after the initial report of successful HIV-positive kidney transplantations in South Africa (13-15); here we focus on a broad set of issues relevant to transplant recipients, donors (deceased and living), and others under this new policy.
HIV-POSITIVE TRANSPLANT RECIPIENTS
The key ethical considerations for HIV-positive transplant recipients relate to access, risk, and consent.
Access
There is a known and substantial burden of endstage organ disease among HIV-positive individuals. Kidney disease is common, affecting up to one third of those infected with HIV (16) . In the United States, an estimated 1.5% of individuals undergoing dialysis are HIV-positive, and this percentage is higher among minority groups, such as African Americans (17) . Similarly, liver disease is a leading cause of death in those with HIV infection, attributable in part to the high prevalence of coinfection with hepatitis B and C viruses in this population (18) .
Evidence suggests that kidney and liver transplantation with HIV-negative donors offers a survival benefit for HIV-positive recipients (19 -22) . However, access to this life-saving treatment is severely limited in general and is exacerbated for those who are HIV-positive, as described earlier. Currently, more than 120 000 individuals overall are awaiting an organ transplant; in 2014 there were fewer than 10 000 deceased organ donors (23) . As a result, many patients die each year on transplant waitlists. This predicament is compounded for persons living with HIV for several reasons. For example, HIV nephropathy primarily affects African Americans (24) , who still encounter disparities in access to kidney transplantation (25) . Furthermore, even in the era of modern ART, HIV-positive individuals have lower survival rates while undergoing dialysis (26) , and therefore their risk for morbidity and mortality while waiting for an organ is higher. The same has been shown for liver disease, with studies demonstrating that HIV infection imparts an additional mortality risk for individuals on the transplant waitlist (27) and that HIV-positive individuals face reduced access to liver transplantation (28) .
The HOPE Act overcomes the legal barrier to use of HIV-positive organs and provides a novel organ supply from HIV-positive donors for HIV-positive individuals to address these disparities. It will allow for experience to be gained in monitored research settings to assess safety and efficacy of these innovative transplantations. Should they prove to be safe, these transplantations could help alleviate the general problem of organ scarcity, potentially benefiting not only persons living with HIV and African Americans in particular but also HIV-negative individuals on the same waitlist because there would be an overall expansion of the donor pool.
Risks
The reported clinical experience with HIV-positive organ transplantations is limited to a total of 27 kidney transplantations performed by using HIV-positive deceased donors at a single center in South Africa (29) . We are unaware of any reports of intentional HIVpositive donor transplantation using organs besides kidneys. Similarly, we are unaware of reported experience with HIV-positive living donors. Although HIVpositive organ recipients originally reported having had good patient and graft survival rates, it is unclear whether this experience will be generalizable. Thus, although HIV-positive-to-HIV-positive transplantations are promising, it remains unclear whether patients will be inadvertently harmed. Accordingly, as experience is garnered, ethical practice demands taking measures to ensure that risks are identified and minimized.
There are physical, psychological, and social risks of HIV-positive-to-HIV-positive transplantations to consider. The risks of necessary immunosuppression after transplantation may be compounded in an HIV-positive individual with a compromised immune system. Data suggest that infection rates, including those of opportunistic infections, are not significantly higher in HIVpositive organ transplant recipients of HIV-negative organs (19) . However, the incidence of immunologic rejection is 2 to 4 times higher in HIV-positive recipients (19, 30) . The mechanism behind the elevated rejection risk is not entirely clear. It may be due to interactions between the pharmacoenhancer ritonavir used in some antiretroviral regimens with the calcineurin inhibitor class used for immunosuppression; this can be avoided by modifying ART regimens (31) . Alternatively, it may be due to underlying immune dysfunction related to HIV infection, which is more complicated to address. Whether rejection will be further exacerbated with use of an HIV-positive organ is unknown.
HIV superinfection (that is, infection with a second strain of HIV) poses an important potential risk (32). If virus from an HIV-positive donor carries drug-resistant Ethics of Organ Transplantation From HIV-Positive Donors MEDICINE AND PUBLIC ISSUES mutations, it may not be controlled by the recipient's ART regimen. In some cases, this might be addressed by changing the recipient's ART; however, safe ART modifications are complicated given the drug interactions discussed earlier. Furthermore, HIV can evolve to use a different cellular receptor to infect cells, a process known as a tropism switch from R5 virus to dual-mixed or X4 tropic virus (33) . Dual-mixed/X4 tropic viruses have been associated with rapid disease progression (34) and are also resistant to maraviroc, an antiretroviral that blocks the R5 receptor. Therefore, not only is superinfection with drug-resistant virus an issue, but superinfection with an X4 tropic strain could also be problematic.
Assessment of such physical or biological risks will be complicated. Organ procurement organizations are the nonprofit organizations responsible for evaluating donors and for recovering organs for transplantation centers. For HIV-positive deceased donors, knowledge regarding the presence of drug resistance or X4 tropic virus may be limited. Although these assays are available clinically, getting results may take several days, and there is a relatively short window during which a team can decide to accept an organ offer. It is possible that this information may be available in the medical record, but historically organ procurement organizations do not have experience reviewing HIV-specific risks and related medical data.
Whether using an HIV-positive donor kidney carries a higher risk for recurrent kidney disease in the HIVpositive recipient is also unknown. In the South Africa cohort, histologic changes similar to those seen in HIVassociated nephropathy have been observed in the transplanted kidney but have not been associated with substantial impairment in kidney function (29) . The risk for HIV-associated nephropathy and focal segmental glomerulosclerosis in African Americans has also been linked to genetic variants of the protein apolipoprotein L1 (35) . Therefore, donor race may also affect outcomes.
The choice of accepting an HIV-positive organ also carries psychological risk because patients must weigh the unknown wait time for an HIV-negative organ versus the fear and unknown biological risks associated with accepting an HIV-positive organ. Such issues may be more vexing in clinical situations where temporizing measures, such as dialysis, are burdensome or unavailable, as in hepatic failure. Furthermore, there are additional ethical factors to consider. For instance, given the biological uncertainty of control of HIV infection of recipients, there could be risks for their sexual partners.
Steps have been taken to minimize such risks. The HOPE Act mandates that HIV-positive-to-HIV-positive transplantations first occur in the context of research, which necessarily adds a level of oversight and additional protections compared with standard clinical practice. The NIH guidelines define minimum outcome data, donor and recipient inclusion criteria, and transplant center requirements for experience with HIVpositive-to-HIV-positive transplantations. Within 2 years, DHHS and OPTN will review research outcomes and determine whether HIV-positive-to-HIV-positive transplantation should be expanded to clinical practice outside of research settings (10, 12) .
Consent
Consistent with the ethical requirement to respect autonomy, the consent process is critical to ensure that patients' decisions are informed and voluntary. Factors to consider include the decision-making capacity of the individual; comprehension of the risks, benefits, and alternatives; and the voluntary nature of the decision. To ensure these criteria are met, an independent recipient advocate is required under the NIH guidelines (12) . This advocate must protect the rights and interests of the potential HIV-positive recipient because investigators and transplant teams may have financial and nonfinancial conflicts of interest in having the patient enroll in the research. It is morally incumbent on those seeking consent to make these conflicts transparent during the consent process and manage them using standard institutional mechanisms.
POTENTIAL HIV-POSITIVE DONORS
For HIV-positive potential donors, there are also ethical challenges and opportunities. For example, respecting the privacy interests of the deceased may be complex when addressing disclosure of HIV-positive status in cases where next of kin may be unaware. With the passage of the HOPE Act, persons living with HIV now have the opportunity, indeed the right, to authorize deceased donation or become living donors under an institutional review board-approved protocol. Thus, the legal prohibition related to restricting donation is removed. This approach is consistent with the recent Food and Drug Administration revision of its lifetime ban on blood donation for men who have had sex with men, changing this to a 1-year blood donor deferral policy (36). Together, these policy shifts are consistent with the principle of justice that compels fairness among equals and may even help mitigate stigma associated with HIV infection.
For any living kidney donor, there is a biological risk for progression to end-stage renal disease after donation, albeit a small one (37) . Whether there would be an additive attributable risk in someone with wellcontrolled HIV infection is unknown. In addition, certain antiretroviral medications should be avoided in patients with compromised renal function, so future HIV treatment options could be limited for some HIVpositive living donors. Given the ethical mandate to avoid harm, these concerns must be identified, discussed with potential donors, and monitored closely.
Beyond physical risks, there are psychological and social risks, such as feeling pressure to donate versus concerns about personal well-being. Similarly, living HIV-positive donors may be especially prone to (or immune from) guilt over transplant failure. Accordingly, a consent process that takes into account these HIVspecific concerns is essential. In addition to mandated MEDICINE AND PUBLIC ISSUES Ethics of Organ Transplantation From HIV-Positive Donors clinical outcomes reporting, social and psychological outcomes should be assessed.
OTHER PATIENTS AND HEALTH CARE WORKERS
Finally, there are potential risks for other patients and for health care workers in permitting such donation. Although concerns have been raised that HIVpositive organs may inadvertently be transplanted into HIV-negative recipients (12) , this has not happened in analogous settings, such as transplantation of hepatitis C virus-positive organs. Similarly, despite universal precautions, there is a worry that health care workers may face excess risk from recovering and transplanting HIVpositive organs. However, organ procurement organizations and hospitals are required to implement policies specifically designed to prevent HIV exposures in health care workers and inadvertent transmission of HIV to HIV-negative recipients (12) .
REALIZING HOPE
The HOPE Act mandates that, for the time being, transplantations using HIV-positive organs occur exclusively within research protocols that are approved by institutional review boards and follow published NIH guidelines. This approach promises an ethically sound way of determining whether this practice is safe and effective while ensuring that the rights and interests of patients and donors are protected. If data from initial studies are favorable, there should be a commitment to more widespread implementation to ensure fair access to therapies. Current author addresses and author contributions are available at www.annals.org.
